Vicinitas Therapeutics will focus on developing differentiated disease therapies based on our targeted protein stabilization platform for stabilizing the levels of aberrantly ubiquitinated and degraded proteins that drive disease pathogenesis. Disease indications will include cancer and stabilizing tumor suppressors, genetic disorders where mutations in a particular gene lead to protein instability and degradation, and haploinsufficiency diseases where slowing the turnover rates of the remaining gene/protein copy would increase protein levels and attenuate the disease.
